Search results for "Butyrates"

showing 10 items of 78 documents

Isolation, biochemical characterization, long-term culture, and phenotype modulation of oval cells from carcinogen-fed rats.

1993

Oval cells are liver epithelial cells that proliferate during hepatocarcinogenesis and chemically induced severe liver injury. It has been suggested that these cells represent hepatic stem cells which might play an important role in the histogenesis of cholangiocellular as well as hepatocellular carcinomas. In order to test this hypothesis highly purified oval cell preparations and propagable oval cell lines are needed. In the present study the isolation, biochemical characterization, and long-term culture of oval cells from rats fed a choline-deficient/DL-ethionine-supplemented diet for 6, 14, or 22 weeks are described. The freshly isolated oval cells were gamma-glutamyltranspeptidase-posi…

MaleCellCell SeparationBiologyCell LineRats Sprague-DawleyCytokeratinchemistry.chemical_compoundLiver Neoplasms ExperimentalmedicineAnimalsDimethyl SulfoxideL-Lactate DehydrogenaseCell growthStem CellsSodium butyrateCell Biologygamma-GlutamyltransferaseMolecular biologyRatsButyratesmedicine.anatomical_structurePhenotypechemistryLiverCell cultureGiant cellImmunologyAlkaline phosphataseButyric AcidKeratinsStem cellExperimental cell research
researchProduct

Investigation of long-range female sex pheromone of the European tarnished plant bug, Lygus rugulipennis: chemical, electrophysiological, and field s…

2004

The European tarnished plant bug, Lygus rugulipennis, is an important pest of agricultural and horticultural crops throughout Europe. Adult male L. rugulipennis were previously shown to be attracted to traps baited with live virgin females, which suggests the females produce a sex pheromone. Volatiles produced by virgin female L. rugulipennis were shown to contain three components, hexyl butyrate, (E)-2-hexenyl butyrate, and (E)-4-oxo-2-hexenal which elicited electroantennographic (EAG) responses from males in analyses by linked gas chromatography–electroantennography (GC-EAG). They were produced in 1.5:1:0.08 ratio, respectively, by single females. Collections from 1, 2, or 4 virgin female…

MaleChromatography GasBiologyBiochemistryPheromonesElectroantennographyToxicologyHemipteraSexual Behavior AnimalBotanyAnimalsLygus rugulipennisEcology Evolution Behavior and SystematicsAldehydesDose-Response Relationship DrugHeteropteraGeneral Medicinebiology.organism_classificationMiridaeButyratesSettore AGR/11 - Entomologia Generale E ApplicataSex pheromonePheromoneFemalePEST analysisTarnished plant bugVolatilizationLygus rugulipennis Heteroptera Miridae tarnished plant bug pheromone electroantennography repellence hexyl butyrate (E)-2-hexenyl butyrate (E)-4-oxo-2-hexenalJournal of chemical ecology
researchProduct

GAS CHROMATOGRAPHIC ESTIMATION OF ACETYLCHOLINE IN THE RABBIT HEART USING A NITROGEN SELECTIVE DETECTOR

1973

The distribution of ACh in the rabbit heart was investigated by a modified gas chromatographic estimation method. ACh was extracted with perchloric acid, precipitated as reineckate and demethylated with sodium benzenethiolate. The tertiary amines derived from ACh and other choline esters were concentrated by a microdistillation procedure. Gas chromatography was performed using a nitrogen selective detector. In the range of concentrations between 0.4 and 2.5 nmol ACh per tissue sample the coefficient of variation was 5.2 per cent. The recovery of ACh added to heart extracts was 101 per cent. Evidence for the identity of the choline ester isolated from rabbit hearts and authentic ACh was obta…

MaleChromatography GasHeart VentriclesCoefficient of variationSodiumchemistry.chemical_elementBlood PressureBiochemistryCholineCellular and Molecular Neurosciencechemistry.chemical_compoundMethodsmedicineAnimalsBioassayCholineHeart AtriaPerchloric acidButyrylcholineChromatographyChemistryMyocardiumAcetylcholineRatsButyratesBiological AssayFemaleRabbitsGas chromatographyPropionatesAcetylcholinemedicine.drugJournal of Neurochemistry
researchProduct

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?

2021

BackgroundCirculating Neprilysin (sNEP) has emerged as a potential prognostic biomarker in heart failure (HF). In PARAGON-HF benefit of sacubitril/valsartan was only observed in patients with left ventricular ejection fraction (LVEF) ≤57%. We aimed to assess the prognostic value of sNEP in outpatients with HF and LVEF >57%, in comparison with patients with LVEF ≤57%.MethodsConsecutive HF outpatients were included from May-2006 to February-2016. The primary endpoint was the composite of all-cause death or HF hospitalization and the main secondary endpoint was the composite of cardiovascular death or HF hospitalization. For the later competing risk methods were used.ResultssNEP was measure…

MalePhysiologyCancer TreatmentCardiovascular MedicineBiochemistrySacubitrilMedical ConditionsClinical endpointMedicine and Health SciencesMultidisciplinaryEjection fractionPharmaceuticsAminobutyratesHazard ratioQRMiddle AgedPrognosisBody FluidsCardiovascular TherapyBloodValsartanOncologyCardiovascular DiseasesCardiologycardiovascular systemMedicineValsartanFemaleNeprilysinAnatomymedicine.drugcirculatory and respiratory physiologyResearch Articlemedicine.medical_specialtyScienceCardiologyDrug TherapyInternal medicinemedicineHumanscardiovascular diseasesAgedProportional Hazards ModelsHeart FailureProportional hazards modelbusiness.industryBiphenyl CompoundsBiology and Life SciencesStroke VolumeCardiovascular Disease Riskmedicine.diseaseHeart failurebusinessSacubitril ValsartanBiomarkersReceptor Antagonist TherapyEjection FractionPloS one
researchProduct

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

2015

Aims: Although active-controlled trials with renin–angiotensin inhibitors are ethically mandated in heart failure with reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared with placebo. The angiotensin receptor-neprilysin inhibitor LCZ696 was compared with enalapril in PARADIGM-HF. We made indirect comparisons of the effects of LCZ696 with putative placebos.\ud \ud Methods and results: We used the treatment-arm of the Studies Of Left Ventricular Dysfunction (SOLVD-T) as the reference trial for comparison of an ACE inhibitor to placebo and the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidit…

MaleTetrazolesAngiotensin-Converting Enzyme InhibitorsEnalaprilEnalapril/therapeutic useMedicineNatriuretic peptidesAngiotensin IIAminobutyratesHeart Failure/CardiomyopathyMiddle AgedAngiotensin Receptor Antagonists/therapeutic useHospitalizationAngiotensin-Converting Enzyme Inhibitors/therapeutic useDrug CombinationsTreatment OutcomeTetrazoles/therapeutic useCardiologyValsartanFemaleCardiology and Cardiovascular Medicinemedicine.drugBenzimidazoles/therapeutic usemedicine.medical_specialtyAngiotensin II Type 1 Receptor Blockers/therapeutic usemedicine.drug_classPlaceboAngiotensin Receptor AntagonistsInternal medicineHumansEnalaprilFASTTrack Clinical ResearchBeta blockerAgedHospitalization/statistics & numerical dataHeart Failurebusiness.industryBiphenyl Compoundsmedicine.diseaseHeart Failure/drug therapyPlacebo EffectAngiotensin IICandesartanEndocrinologyAminobutyrates/therapeutic useHeart failureACE inhibitorBenzimidazolesbusinessAngiotensin II Type 1 Receptor BlockersSacubitril ValsartanNatriuretic peptide
researchProduct

Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.

1993

AbstractThe active metabolite of leflunomide, A77 1726 inhibits the proliferation of a variety of mammalian cell lines in culture. Epidermal growth factor (EGF)-dependent proliferation is inhibited by A77 1726 at an effective dose of 30–40 μM. A77 1726 appears to directly inhibit the EGF receptor tyrosine-specific kinase activity both in intact cells and purified EGF receptors at the same effective dose. These data suggest that leflunomide inhibits cellular proliferation by the inhibition of tyrosine-specific kinase activities.

MaleToluidinesmedicine.medical_treatmentBiophysicsHydroxybutyratesBiochemistryKB CellsCell LineHuman foreskin fibroblast cellStructural BiologyEpidermal growth factorNitrilesGeneticsmedicineTumor Cells CulturedAnimalsHumansEpidermal growth factor receptorKinase activityPhosphorylationReceptorMolecular BiologyCells CulturedSkinAniline CompoundsbiologyCell growthKinaseEpidermal growth factor receptorGrowth factorAnti-Inflammatory Agents Non-SteroidalCell BiologyIsoxazolesFibroblastsTyrosine-specific kinaseCell biologyErbB ReceptorsBiochemistryCrotonatesbiology.proteinCarcinoma Squamous CellPlatelet-derived growth factor receptorLeflunomideFEBS letters
researchProduct

Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients.

2022

Purpose Only a few studies are available on dose-related effects of sacubitril/valsartan (angiotensin receptor neprilysin inhibition (ARNI)) in real-life patients with heart failure and reduced ejection fraction (HFrEF). We sought to investigate clinical and functional effects in real-life HFrEF patients receiving ARNI at a different cumulative dose. Methods This was an observational study in consecutive outpatients admitted for HFrEF from October 2017 to June 2019. The PARADIGM criteria were needed for enrolment. ARNI was uptitrated according to blood pressure, drug tolerability, renal function and kaliemia. At least 10-month follow-up was required in each patient. Clinical assessment, Kan…

Malemedicine.medical_specialtyARNIBlood PressureWalk TestComorbiditySacubitrilVentricular Function LeftAngiotensin Receptor AntagonistsInternal medicinemedicine6-min walking test Aged Aminobutyrates Angiotensin Receptor Antagonists ARNI Biphenyl Compounds Blood Pressure Comorbidity Dose-Response Relationship Drug Drug Combinations Echocardiography Female Heart failure Humans Left ventricular function Male Middle Aged Prospective Studies Sacubitril/valsartan Stroke Volume Valsartan Ventricular Function Left Walk TestHumansPharmacology (medical)Sacubitril/valsartanProspective Studies6-min walking testAgedPharmacologyHeart FailureEjection fractionDose-Response Relationship DrugCumulative dosebusiness.industryAminobutyratesLeft ventricular functionBiphenyl CompoundsStroke VolumeGeneral MedicineMiddle Agedmedicine.diseaseClinical TrialARNI heart failure left ventricular function 6-minutes walking test Sacubitril/valsartan.Drug CombinationsBlood pressureTolerabilityValsartanEchocardiographyHeart failureCardiologyValsartanFemalebusinessSacubitril Valsartanmedicine.drugEuropean journal of clinical pharmacology
researchProduct

Evaluation of the therapeutic potential of PPARalpha agonists for X-linked adrenoleukodystrophy.

2003

Adrenoleukodystrophy protein (ABCD1), a peroxisomal membrane protein, is mutated in patients affected by X-linked adrenoleukodystrophy (X-ALD). Adrenoleukodystrophy-related protein (ABCD2) is the closest relative of ABCD1. Pharmacological induction of ABCD2 gene expression has been proposed as a novel therapy strategy for X-ALD. Fibrates induce peroxisome proliferation and Abcd2 expression in rodent liver. Here we evaluate the possibility of using peroxisome proliferator-activated receptor alpha (PPARalpha) agonists for pharmacological induction of ABCD2 expression. In the liver of PPARalpha-deficient mice, both the constitutive and the fenofibrate-inducible Abcd2 gene expression was found …

Malemedicine.medical_specialtyEndocrinology Diabetes and MetabolismMolecular Sequence DataDrug Evaluation PreclinicalPeroxisome ProliferationReceptors Cytoplasmic and NuclearBiologySulfidesATP Binding Cassette Transporter Subfamily DResponse ElementsBiochemistrychemistry.chemical_compoundMiceEndocrinologyInternal medicineGene expressionGeneticsmedicineAnimalsAdrenoleukodystrophyMolecular BiologyGenePhenylurea CompoundsTetradecylthioacetic acidBrainmedicine.diseaseMolecular biologyIntronsMice Mutant StrainsSterol regulatory element-binding proteinDNA-Binding ProteinsMice Inbred C57BLButyratesSterolsEndocrinologychemistryGene Expression RegulationLiverCCAAT-Enhancer-Binding ProteinsSterol Regulatory Element Binding Protein 1AdrenoleukodystrophyATP-Binding Cassette TransportersSterol regulatory element-binding protein 2Sterol Regulatory Element Binding Protein 1Sterol Regulatory Element Binding Protein 2Transcription FactorsMolecular genetics and metabolism
researchProduct

The Effect of Indobufen on the Activities of Selected Rat Liver Phase I and Phase II Drug Metabolizing Enzymes, Peroxisomal β-oxidation and Hepatic G…

1994

Abstract Oral administration of indobufen to male rats for three days at daily doses of 5, 10 and 20 mg kg−1 resulted in no changes in liver total glutathione, cytosolic glutathione S-transferases or microsomal epoxide hydrolase. Reduced glutathione appeared slightly diminished to about 84% of control at the highest dose level. Microsomal cytochrome P450-dependent ethoxyresorufin O-de-ethylase and pentoxyresorufin de-alkylase activities were decreased to 64% (not significantly) and 67% of control at the lowest dose level. 6α- and 7α-Hydroxytestosterone activities were decreased to 67 and 68% of control at the highest dose level. Cyanide-insensitive peroxisomal fatty acid β-oxidation was inc…

Malemedicine.medical_specialtyPharmaceutical ScienceIsoindolesBiologyMicrobodieschemistry.chemical_compoundCytochrome P-450 Enzyme SystemOral administrationInternal medicinemedicineAnimalsGlutathione TransferaseEpoxide HydrolasesPharmacologychemistry.chemical_classificationIndobufenDose-Response Relationship DrugFatty AcidsFatty acidCytochrome P450Rats Inbred StrainsGlutathionePeroxisomeGlutathionePhenylbutyratesRatsEndocrinologyLiverchemistryMicrosomal epoxide hydrolaseMicrosomebiology.proteinOxidation-Reductionmedicine.drugJournal of Pharmacy and Pharmacology
researchProduct

Sacubitril/valsartan and short-term changes in the 6-minute walk test: A pilot study

2018

Background: Impaired exercise capacity is the most disabling symptom in patients with heart failure with reduced ejection fraction (HFrEF). Despite sacubitril/valsartan showing reduced long-term morbidity and mortality over enalapril in HFrEF, its effects on short-term functional capacity remain uncertain. We sought to evaluate the effects of sacubilril/valsartan on a 30-day six-minute walk test in eligible patients with HFrEF. Methods and results: From November 1, 2016 to February 1, 2017, a total of 58 stable symptomatic patients with HFrEF were eligible for sacubitril/valsartan and underwent 6-MWT before and 30 days after initiation of sacubitril/valsartan therapy. A mixed-effects model …

Malemedicine.medical_specialtyTime FactorsTetrazolesPilot ProjectsWalk Test030204 cardiovascular system & hematologySacubitrilCohort Studies03 medical and health sciencesAngiotensin Receptor AntagonistsElectrocardiography0302 clinical medicineInternal medicineExercise capacityMedicineHumans6-minute walk test030212 general & internal medicineEnalaprilProspective StudiesSacubitril/valsartanAgedAged 80 and overEjection fractionExercise Tolerancebusiness.industryAminobutyratesBiphenyl CompoundsExercise capacityMiddle Agedmedicine.diseaseHeart failure with reduced ejection fractionDrug CombinationsTreatment OutcomeValsartanHeart failureCardiologyValsartanFemaleCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drug
researchProduct